Dr. Elisabeth George, Technical Adviser, NICE
Trevor Leighton, VP Pricing & Reimbursement, Shire
Anne-Toni Rodgers Director, Government Affairs and Public Policy - Europe, Baxter
Dr. Rainer Walenta, Director Global Pricing & Reimbursement, Solvay Pharmaceuticals
Dr. Jacco Keja, Managing Director and Practice Leader, Quintiles Global Consulting Services
Martin Egler, Director Pharmacoeconomics, Pricing & Reimbursement Central Strategic Marketing CNS, Merz Pharmaceuticals
Tony Woodgate, Partner, Simmons & Simmons
Keith Tolley, Director, THEMA
Dr. Boyan Doganov, Director, International Projects, The International Health Care & Health Insurance Research Institute
Dr. Sabine Vogler, ÖBIG, Austrian Institute of Health
George Wyatt, Managing Director, Wyatt Health Management
Dirk Kars, Partner, Simon-Kucher & Partners
Dr Brian Lovatt, Managing Director, Cancer Deals

Now in its seventh year, Visiongain’s 7th Annual Pricing & Reimbursement conference, will provide you with the information and analysis you need to understand the dynamics of the market and create an effective pricing policy. This 2-day event will assist in better planning and marketing strategy and enable executives to share their insights on this evolving industry issue.

Key themes include:

• HE requirements in major markets and the role of HE in determining pricing / reimbursement
• Protecting innovation: Product lifecycle price strategy
• Pricing and reimbursement of oncology drugs
• Focus on the requirements of specific pricing strategies: Europe, USA, and Japan
• Producing an effective global strategy to gain market share Pricing and reimbursement continues to be one of the most talked about industry issues. I invite you to book now to avoid missing out on this premier event. I look forward to seeing you there Yours sincerely

Understand of the healthcare market dynamics and P&R environment
Gain insight into how P&R fits into company strategy and understand how
specific P&R trends are shaping the European and US markets
Hear critical information needed to arrive at the most effective strategy
Make the most profitable decisions
Participate in a range of networking opportunities

Who Should Attend:

Companies:
• Pharmaceutical and Biotechnological Companies
• Drug Regulators, Health Care Agencies and Medical Insurance Funds
• Contract Sales/ Marketing Organisations

Job Titles:
Directors, Heads and Managers of:
• Pricing and Reimbursement
• Strategic Pricing
• Price Monitoring
• Reimbursement & Market Access
• Research and Development
• Health Economics
• Economics and Government Affairs
• International Trade and Market Policy
• Parallel Trade
• Business Strategy
• Sales & Marketing
• Corporate Strategy
• Regulatory Affairs
• Outcomes Research
• Health Policy Advisors
• Analysts

Day 1

7th Annual Pricing & Reimbursement Conference

Tuesday 30th September 2008

09:30 Registration and refreshments

10:00 Opening address from the chair

10:10 Reimbursement issues for oncology drugs • Evaluate what payer measures for cost-containment in oncology have already been taken or are being planned for the future • Maximize the chance of your drug gaining positive payer decisions by recognizing the influences on the reimbursement/funding decision-making process • Understand how the oncology pricing and reimbursement environment may evolve over the next five years Dirk Kars

Partner

Simon-Kucher & Partners 10:50 Key competition and EU Law developments • When can dominant companies use Quota Schemes? • The AstraZeneca decision and appeal - dominance

exposure in pharma • Dual picing strategies-latest developments • The Sector Inquiry-likely outcomes and implications Tony Woodgate

Partner

11:30 Morning refreshments

11:50 UK PPRS Reform • PPRS current status of negotiations and next steps • Value based decision making - a reality? • NICE, Government and Industry, what are there roles and responsibilities?

Anne-Toni Rodgers
Director, Government Affairs and Public Policy - Europe
Baxter

12:30 Using HE to support product value demonstration

• Importance of health economics for product market access
• Planning a health economic strategy for product value demonstration
• Communication strategies
• Value based pricing Keith Tolley

Director

13:10 Networking lunch

14:30 Pharmaceutical pricing & innovation; Magic, muddle or method?

Trevor Leighton
Vice President Pricing & Reimbursement
Shire

15.10 Understanding pricing and reimbursement issues of biosimilars

• Biosimiliar market access: differences between the US and the EU
• Payer perception of biosimiliars
• The impact of biosimiliars: case studies from the EU
• Finding the right strategic response

Dr. Jacco Keja Managing Director and Practice Leader Quintiles Global Consulting Services

15:50 Afternoon refreshments

16:10 Strategies on rational use and cost-containment
• Introduction on key pricing and reimbursement mechanisms in the EU Member States
• Major initiatives and reforms regarding rational use of pharmaceuticals and/or cost-containment
• Discussing their effects and impact
• Outlook

16:50 Strategies for achieving the most effective patent protection
• Regulatory issues to consider when seeking patent protection
• Claim drafting strategies
• Protecting from design arounds by using method and process claims
• Use of trade secret protection
17:40 Closing remarks from the chair

17:45 Networking Drinks Reception

Take your discussions further and build new relationships in a relaxed and informal setting.

7th Annual Pricing & Reimbursement Conference

Wednesday1st October 2008

09:30 Registration and refreshments
10:00 Opening address
10:10 How to develop an effective pricing and reimbursement strategy

• Market access - critical success factors
• What payers are looking for
• Commonly used techniques / procedures
• Payers are setting the rules

Martin Egler Director Pharmacoeconomics, Pricing & Reimbursement Central Strategic Marketing CNS Merz Pharmaceuticals

10:50 Pricing and reimbursement series: NICE its impact on the UK healthcare system and beyond
• Overview of the UK pricing and reimbursement system and the role NICE plays in it
• Analysis of the key issues facing NICE and the measures being taken to rectify them
• Discussion of case studies to illustrate the effect of and response to key NICE rulings

Dr. Elisabeth GeorgeTechnical AdviserNICE

11:30 Morning refreshments
11:50 The impact of different European pricing and reimbursement systems on the pharma industry

Dr. Rainer Walenta Director Global Pricing & Reimbursement Solvay
12:30 Pricing and reimbursement in North America

• The proven techniques that can predict the long term
• Understanding the risks involved
• Resulting predictions for the US pricing environment in the USA

13:10 Networking lunch
14:30 Canadian pharmaceutical reimbursement – From CDR to success

• Overview of pharmaceutical reimbursement in Canada
- Public and private markets
- How Canada’s public reimbursement compares within the OECD
• The Common Drug Review (CDR) – Gateway to public reimbursement
- What is the Common Drug Review (CDR), what does it do and where is it going?
- The impact of a CDR recommendation on public reimbursement
• Canada’s national pharmaceuticals strategy
- Behind the rhetoric – what you need to know
• Reimbursement strategies
- How you can succeed in the Canadian market
George WyattManaging DirectorWyatt Health Management

15:10 Current pricing and reimbursement in Bulgaria and neighbouring countries
• Current P&R systems implemented
• Role of EU guidance
• Pros and cons
• Future trends analysis for Balkan pharmaceutical market

Dr. Boyan DoganovDirector, International ProjectsThe International Health Care & Health Insurance Research Institute

15:50 Afternoon refreshments
16:10 Current P&R strategies in Japan: what are the key issues?
• Examining the structure of the Japanese pharmaceutical market
• Implementing strategies to suit the market
• Forecasting market growth and future trends
16:50 The impact of parallel trade on pricing strategy
• Where does parallel trade fit in a global pricing strategy?
• Exploring developments in European parallel trade
• Tactical options for pricing managers to monitor and manage parallel trade

Dr Brian LovattManaging DirectorCancer Deals

17:30 Chair’s closing remarks
17:40 End of conference